EICHORCondition: HER2-positive Solid Tumors · Sponsor: Voronoi, Inc
This FIH open-label study aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor effect of VRN101099 in patients with HER2-positive solid tumors for whom no standard therapies are available.
This description comes directly from the study's public registry record.
Rutu Dabhi · +1 201-515-9340 · dabhirutu@voronoi.io
Always discuss trial participation with your own doctor first.
| St Vincent's Hospital Sydney | Darlinghurst, New South Wales, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06806982